What Analysts Say about the Matinas BioPharma Holdings Inc. (MTNB) Stock

Matinas BioPharma Holdings Inc. (AMEX:MTNB) saw an upside of 9.43% to close Monday at $1.16 after adding $0.1 on the day. The 5-day average trading volume is 2,306,140 shares of the company’s common stock. It has gained $1.2500 in the past week. An average of 4,485,455 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,610,478.

MTNB’s 1-month performance is 40.44% or $0.3340 on its low of $0.8900 reached on 09/13/21. The company’s shares have touched a 52-week low of $0.67 and high of $2.22, with the stock’s rally to the 52-week high happening on 01/05/21. YTD, MTNB has lost -14.71% or -$0.2000. However, the current price is down -47.75%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Valuation Metrics

Matinas BioPharma Holdings Inc. (MTNB) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.MTNB stock has a beta of 2.33. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1268.87 while the price-to-book (PB) in the most recent quarter is 3.74.

Matinas BioPharma Holdings Inc.’s quick ratio for the period ended June 29 was 17.00, with the current ratio over the same period at 17.00 meaning that MTNB stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -14799.16%. The firm’s gross profit as reported stood at $24.36 million against revenue of $0.16 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Matinas BioPharma Holdings Inc.’s cash and short-term investments amounted to $29.49 million against total debt of $3.51 million. Analysts expected MTNB to announce -$0.03 per share in earnings in its latest quarter, but it posted -$0.02, representing a 33.30% surprise. EBITDA for the quarter stood at more than -$4.55 million. MTNB stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 7.07 million, with total debt at $3.51 million. Shareholders hold equity totaling $214.74 million

Technical Picture

Let’s look briefly at Matinas BioPharma Holdings Inc. (MTNB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 51.16% to suggest the stock is trending Neutral, with historical volatility in this time period at 96.88%.

The stock’s 5-day moving average is $1.0880, reflecting a +6.42% or $0.0700 change from its current price. MTNB is currently trading +10.48% above its 20-day SMA, +47.15% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +64.24% and +18.83% respectively.

Stochastic %K and %D was 10.98% and 8.69% and the average true range (ATR) pointed at 0.1278. The RSI (14) points at 53.51%, while the 14-day stochastic is at 22.41% with the period’s ATR at 0.1207. The stock’s 9-day MACD Oscillator is pointing at -0.0467 and -0.1521 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Matinas BioPharma Holdings Inc. (AMEX: MTNB), Piper Sandler downgraded it to a Neutral rating. They previously had an Overweight rating on the stock. Analysts offering their rating for MTNB stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate MTNB as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.

What is MTNB’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $0.90 and a high of $3.00, with their median price target at $3.00. Looking at these predictions, the average price target given by analysts is for Matinas BioPharma Holdings Inc. (MTNB) stock is $2.38.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam